Melanoma

New data on combination treatments for melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according ...

Sep 29, 2014
popularity not rated yet | comments 0
  • Pages: 1 2

Latest Spotlight News